Geneva, January 15, 2015

2014 FULL-YEAR PRESS RELEASE

Activity

Sales

2014 worldwide revenues grew 15% compared to 2013. Direct sales in Europe grew 53% and, despite continued price pressure, direct sales in the USA grew 14% in USD.

Total revenues in EMEA grew 30%. Sales to distributors in Latin America decreased 22% due to adverse currency and political environment and grew 5% in Asia-Pacific.

Surgeries

The total number of cervical disc BAGUERA®$_{C}$ successfully implanted since launch exceeded 12,500 while the ISPF ROMEO®2 $_{PAD}$ reached 2,600 successful implantations. SCARLET®$_{AC-T}$, a secured cervical cage in titanium commercially launched in September in Europe and in December in the US, reached more than 500 successful implantations.

Gross Margin and Operating Profit

Non-audited gross margin and EBITDA margin stand respectively at 80% and 11% of sales.

Technology Platforms

In 2014, Spineart maintained its ranking as one of the most innovative spine companies in the market.

The company received approval from the US FDA for 9 additional products, including a full titanium ISPF ROMEO®2 $_{PAD}$, a full titanium secured cervical cage SCARLET®$_{AC-T}$ and a full titanium Lateral cage JULIET®$_{LL}$. These approved products will be progressively released in the USA throughout 2015.

Spineart also completed CE-marking for 10 new products, and initiated limited products release for a novel Vertebral Compression Fracture treatment system, TEKTONA® and a new ROMEO®2 fenestrated pedicle screw.

In March 2014, Spineart received approval from the Chinese CFDA for its cervical cage TRYPTIK®$_{CA}$ and cervical cage-plate TRYPTIK®$_{MC}$. In August, Spineart received approval from the Brazilian ANVISA for its ISPF ROMEO®2 $_{PAD}$. In December, the company received approval from the India DCGI office for its posterior lumbar cages range JULIET®, its pedicle screws systems ROMEO®2 and ROMEO®2 $_{MIS}$, its cervical disc BAGUERA®$_{C}$ and its fusion cervical range TRYPTIK®.

Prospect

In 2015 Spineart will be celebrating 10 years of business, a truly momentous occasion. Spineart anticipates continued double-digit growth backed by the continued expansion of its product portfolio, the introduction of new technologies and the strengthening of its sales network.

About Spineart

Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams and patients.

Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of Minimally Invasive Surgery, Motion Preservation, Fusion, Biologics and Fractures Treatment.

Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency and compliance at the hospital.